TICKERNERD
Menu
BLFSBLFSHealthcare · Medical Instruments & Supplies

BLFS Stock Forecast: BioLife Solutions, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$37
+0.32% on the day

The 9 Wall Street analysts covering BioLife Solutions, Inc. hold a median 12-month price target of $31 — -16.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 22 Aug 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
91 / 100
Median analyst target
$31
Analysts covering
9
Total return, dividends reinvested
1W
+5.8%
1M
+27.1%
YTD
+53.4%
1Y
+47.9%
From 52W high
0.0%
From 52W low
+104.4%
$18
$37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BLFS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioLife Solutions, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
91
Revisions
87
Momentum
84
Growth
80
Issuance
71
Value
69
Volatility
68
Size
38
Accruals
19

Quality (91): The business earns solid, repeatable profits on what it owns.

Accruals (19): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLFS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLFS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26BLFSHigh $33Median $31Low $31

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
1 Buy8 Hold0 Sell
Low $31Median $31High $33

The green dot is the last close — the median target sits −16.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
10 Aug 2026BenchmarkDowngradeHold—
27 July 2026Stephens & Co.DowngradeEqual-Weight—
27 July 2026Stephens & Co.DowngradeEqual-Weight$32 → $31
23 July 2026JefferiesDowngradeHold$30 → $31
23 July 2026JefferiesDowngradeHold—
23 July 2026TD CowenDowngradeHold—
23 July 2026TD CowenDowngradeHold$33 → $31
22 July 2026HC Wainwright & Co.DowngradeNeutral—
22 July 2026HC Wainwright & Co.DowngradeNeutral$32 → $31
22 July 2026Lake StreetDowngradeHold—
22 July 2026Lake StreetDowngradeHold$33 → $31
29 Dec 2025HC Wainwright & Co.ReiteratesBuy$32
29 Dec 2025HC Wainwright & Co.ReiteratesBuy—
24 Nov 2025HC Wainwright & Co.ReiteratesBuy—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
13 May 2025HC Wainwright & Co.ReiteratesBuy—
6 Mar 2025HC Wainwright & Co.MaintainsBuy—
8 Jan 2025Northland Capital MarketsMaintainsOutperform—
19 Dec 2024BenchmarkReiteratesBuy—
13 Dec 2024KeybancMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLFS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BLFS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+50.0%
Analysts raising
0
Analysts cutting
1
Fundamentals

BioLife Solutions, Inc. (BLFS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
37.1×

Cheaper than 21% of US stocks

Price / sales
17.0×

Cheaper than 10% of US stocks

Price / book
4.3×

Cheaper than 25% of US stocks

EV / EBITDA
253.3×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
21.5%

Higher than 71% of US stocks

Earnings growth (YoY)
12.0%

Higher than 50% of US stocks

Gross margin
64.2%

Higher than 78% of US stocks

Operating margin
6.0%

Higher than 57% of US stocks

Net margin
54.3%

Higher than 96% of US stocks

Returns & dividend
Return on equity
12.8%

Higher than 70% of US stocks

Return on assets
0.3%

Higher than 44% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BLFS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
BLFSBioLife Solutions, Inc.$1.8B
91
LMATLeMaitre Vascular, Inc.$1.9B
75
AZTAAzenta, Inc.$1.7B
80
KMTSKestra Medical Technologies Ltd.$1.6B
21
XRAYDentsply Sirona, Inc.$2.2B
91
ATRCAtriCure, Inc.$2.5B
94
STAASTAAR Surgical Co.$1.2B
80

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioLife Solutions, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLFS news & analysis

BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates

Zacks Investment Research · 6 Aug 2026positive

BioLife Solutions, Inc. reported second-quarter earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share. This compares with break-even earnings per share in the same quarter a year earlier.

Why it matters — The results represent a clear improvement over both analyst expectations and the prior-year period, which a BLFS watcher would find notable.

BioLife Solutions Reports Second Quarter 2026 Financial Results

PRNewsWire · 6 Aug 2026positive

BioLife Solutions reported second quarter 2026 financial results, with total revenue of $28.5 million, up 21% over Q2 2025, GAAP gross margin of 64%, and non-GAAP adjusted EBITDA of $7.4 million. The company also noted that Repligen is expected to acquire BioLife, with the transaction expected to close in the fourth quarter of 2026.

Why it matters — A BLFS watcher would care because the results show revenue growth and profitability, while the announced Repligen acquisition represents a major corporate development expected to close in late 2026.

The London Company Large Cap Vs. Russell 1000 Q2 2026 Portfolio Review

Seeking Alpha · 5 Aug 2026neutral

The London Company's Large Cap portfolio returned 10.9% in Q2 2026 versus a 15.1% increase in the Russell 1000 Index. The firm highlighted ENTG as a top contributor on improving fab utilization and AI-driven semiconductor demand, while RSG declined despite a solid quarter due to softer Environmental Solutions results and weak construction-related volumes.

Why it matters — BioLife Solutions is not mentioned in this portfolio review, so the report offers no direct insight into BLFS; however, BLFS watchers may find it useful for general market context on fund positioning.

Diamond Hill Small Cap Fund Q2 2026 Portfolio Activity

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha's Diamond Hill Small Cap Fund Q2 2026 portfolio activity report discusses performance of Astrana Health and Magnolia Oil & Gas, along with a new position in Insteel Industries, but does not mention BioLife Solutions, Inc. (BLFS).

Why it matters — BLFS watchers may find the report's lack of coverage notable if they follow Diamond Hill's moves for insight into small-cap investing sentiment.

BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS

Business Wire · 24 July 2026negative

Law firm Kahn Swick & Foti is investigating the proposed sale of BioLife Solutions to Repligen Corporation, and is seeking to determine the adequacy of the price and process in the transaction.

Why it matters — BLFS shareholders may be affected by the outcome of this investigation into whether the terms of the proposed acquisition fairly value their shares.

FAQ

Frequently asked questions about BLFS stock

What is the BLFS stock price forecast for 2026-2027?

The 9 Wall Street analysts covering BioLife Solutions, Inc. have a median 12-month price target of $31, with estimates ranging from $31 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLFS stock a buy right now?

Of the 9 analysts covering BioLife Solutions, Inc., 1 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioLife Solutions, Inc. 91 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLFS?

As at 22 Aug 2026, BioLife Solutions, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (91 of 100).

Will BLFS stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -16.4% from the last close, and Ticker Nerd's factor model ranks BioLife Solutions, Inc. 91 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLFS stock forecast for 2030?

No analyst covering BioLife Solutions, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLFS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $33 over the next 12 months.

How has BLFS stock performed over the past year?

BioLife Solutions, Inc. returned +47.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioLife Solutions, Inc. do?

Biolife Solutions Inc. is a leading provider of cell and gene therapy bioproduction tools and services.

What is the latest news on BLFS?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "BioLife Solutions, Inc. (BLFS) Q2 Earnings and Revenues Surpass Estimates". BioLife Solutions, Inc. reported second-quarter earnings of $0.04 per share, surpassing the Zacks Consensus Estimate of a loss of $0.01 per share. This compares with break-even earnings per share in the same quarter a year earlier.

Company

About BioLife Solutions, Inc.

Biolife Solutions Inc. is a leading provider of cell and gene therapy bioproduction tools and services. It specializes in offering biopreservation media, automated thawing devices, and storage solutions that are essential for preserving and transporting biological materials. The company's products help enhance the quality and stability of biological samples, which is crucial in sectors like regenerative medicine, biobanking, and drug discovery. By ensuring the safe handling and preservation of cells, tissues, and organs, Biolife Solutions plays a pivotal role in supporting life science research and clinical applications. The company's innovations contribute significantly to advancing therapeutic research and the development of treatments, thereby impacting the healthcare industry extensively. Headquartered in Bothell, Washington, Biolife Solutions Inc. is strategically positioned in the market, facilitating the evolving needs of the biopharmaceutical sector worldwide.

CEO Mr. Roderick de Greef · 155 employees · United States · https://www.biolifesolutions.com